Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Anusha Ande"'
Autor:
Anusha Ande, Tanaya R. Vaidya, Bao N. Tran, Michael Vicchiarelli, Ashley N. Brown, Sihem Ait-Oudhia
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Background: Emergence of Human epidermal growth factor receptor 2 (HER2) therapy resistance in HER2-positive (HER2+) breast cancer (BC) poses a major clinical challenge. Mechanisms of resistance include the over-activation of the PI3K/mTOR and Src pa
Externí odkaz:
https://doaj.org/article/1a6dd700031345f0ae84cef24ea7a1b6
Autor:
Anantha R Nookala, Junhao Li, Anusha Ande, Lei Wang, Naveen K Vaidya, Weihua Li, Santosh Kumar, Anil Kumar
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146529 (2016)
Cytochrome P450 3A4 (CYP3A4) is the major drug metabolic enzyme, and is involved in the metabolism of antiretroviral drugs, especially protease inhibitors (PIs). This study was undertaken to examine the effect of methamphetamine on the binding and me
Externí odkaz:
https://doaj.org/article/d97bf9ea78df4766bcacd3418dbeeeab
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155791 (2016)
While cigarette smoking is prevalent amongst HIV-infected patients, the effects of cigarette smoke constituents in cells of myeloid lineage are poorly known. Recently, we have shown that nicotine induces oxidative stress through cytochrome P450 (CYP)
Externí odkaz:
https://doaj.org/article/05f29e6f34af42709f107ad744dee979
Autor:
Anusha Ande, Carole McArthur, Leo Ayuk, Charles Awasom, Paul Ngang Achu, Annette Njinda, Namita Sinha, P S S Rao, Marisela Agudelo, Anantha Ram Nookala, Stephen Simon, Anil Kumar, Santosh Kumar
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0122402 (2015)
Mild-to-moderate tobacco smoking is highly prevalent in HIV-infected individuals, and is known to exacerbate HIV pathogenesis. The objective of this study was to determine the specific effects of mild-to-moderate smoking on viral load, cytokine produ
Externí odkaz:
https://doaj.org/article/14659e734ea74806bc6a0d9bd20a1bc2
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 369:531-545
The emergence of human epidermal growth factor receptor type-2 (HER2) therapy resistance in HER2-positive (HER2+) breast cancer (BC) poses a major clinical challenge. The primary mechanisms of resistance include aberrant activation of the HER2 and ph
Autor:
R. Angelo de Claro, Richard Pazdur, Nicholas Richardson, Chao Liu, Gregory H. Reaman, Margret Merino, Anusha Ande, Simbarashe Zvada, Sudharshan Hariharan, Ann T. Farrell
Publikováno v:
Pediatric bloodcancerREFERENCES. 67(12)
On May 16, 2019, the U.S. Food and Drug Administration (FDA) approved dalteparin sodium for the treatment of symptomatic venous thromboembolism (VTE) to reduce the risk of recurrence in pediatric patients 1 month of age and older. Approval was primar
Publikováno v:
The FASEB Journal. 33
Publikováno v:
Molecular pharmacology. 96(2)
Doxorubicin (DOX) is one of the most effective anticancer drugs to treat various forms of cancers; however, its therapeutic utility is severely limited by its associated cardiotoxicity. Despite the enormous amount of research conducted in this area,
Autor:
Sihem Ait-Oudhia, Ashley N. Brown, Bao N Tran, Anusha Ande, Michael Vicchiarelli, Tanaya R Vaidya
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 9 (2018)
Frontiers in Pharmacology, Vol 9 (2018)
Background: Emergence of Human epidermal growth factor receptor 2 (HER2) therapy resistance in HER2-positive (HER2+) breast cancer (BC) poses a major clinical challenge. Mechanisms of resistance include the over-activation of the PI3K/mTOR and Src pa
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 45(4)
Dysregulation of mTOR pathway is common in hepatocellular carcinoma (HCC). A translational quantitative systems pharmacology (QSP), pharmacokinetic (PK), and pharmacodynamic (PD) model dissecting the circuitry of this pathway was developed to predict